Literature DB >> 7746285

Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis.

H M Beere1, C M Chresta, A Alejo-Herberg, A Skladanowski, C Dive, A K Larsen, J A Hickman.   

Abstract

Apoptosis is characterized by the nonrandom cleavage of DNA. After continuous treatment of MOLT-4 human T lymphoblastoid cells with the topoisomerase II inhibitor etoposide (50 microM) and the nongenotoxic agent N-methylformamide (300 mM), apoptosis was confirmed by electron microscopy. Analysis of DNA integrity by conventional gel electrophoresis failed to detect internucleosomal DNA cleavage. Resolution of DNA by field inversion gel electrophoresis showed fragments of 50 kilobases (kb). Etoposide induced the transient appearance of an additional DNA band of > 600 kb, which was temporally coincident with DNA-protein complex formation and was rapidly reversible upon drug removal. This DNA band was not observed after N-methylformamide treatment. In situ DNA end-labeling showed the incorporation of biotinylated dUTP into 50-kb DNA fragments but not etoposide-induced DNA fragments of > 600 kb. DNA end-labelling with terminal deoxynucleotidyltransferase was therefore not dependent upon intenucleosomal DNA cleavage, and fragments of approximately 50 kb were characterized by free 3'-OH termini that were not occluded by topoisomerase II protein. Although we considered that topoisomerase II potentially played an active role in the fragmentation of higher order chromatin during apoptosis, the results showed that DNA cleavage by topoisomerase II induced reversible, protein-associated fragments of > 600 kb and not irreversible cleavage to 50-kb fragments. The reversible cleavage of DNA to fragments of > 600 kb appears to be a signal for the engagement of apoptosis and is not an initial step in the sequential unwinding of chromatin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7746285

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

Review 1.  Forces on chromosomal DNA during anaphase.

Authors:  G Jannink; B Duplantier; J L Sikorav
Journal:  Biophys J       Date:  1996-07       Impact factor: 4.033

Review 2.  H2O2-induced higher order chromatin degradation: a novel mechanism of oxidative genotoxicity.

Authors:  Gregory W Konat
Journal:  J Biosci       Date:  2003-02       Impact factor: 1.826

3.  DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis.

Authors:  M Stanulla; J Wang; D S Chervinsky; S Thandla; P D Aplan
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

4.  Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia.

Authors:  R Strick; P L Strissel; S Borgers; S L Smith; J D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

5.  Nucleotides induce higher order chromatin degradation.

Authors:  Monika Banaszewska; Gregory W Konat
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

6.  Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death.

Authors:  Holly A Porter; Gregory B Carey; Achsah D Keegan
Journal:  Exp Cell Res       Date:  2012-05-28       Impact factor: 3.905

7.  Drug-induced death of leukaemic cells after G2/M arrest: higher order DNA fragmentation as an indicator of mechanism.

Authors:  R J Sleiman; D R Catchpoole; B W Stewart
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

Review 8.  Higher order chromatin degradation: implications for neurodegeneration.

Authors:  Gregory W Konat
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

9.  IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors.

Authors:  Holly A Porter; Anthony Perry; Chris Kingsley; Nhan L Tran; Achsah D Keegan
Journal:  Cancer Lett       Date:  2013-04-02       Impact factor: 8.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.